Nanox Expands in Latin America with Exclusive Nanox.ARC Distribution Agreement in Argentina

Collaboration with Intec SRL drives commercial expansion of 3D medical imaging across a high-growth private healthcare market PETACH TIKVA, Israel, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Nanox Imaging Ltd. (“Nanox”, Nasdaq: NNOX), a leader in innovative medical imaging technology, today announced a distribution agreement with Intec SRL, an Argentina-based medical device distributor with more than 35 years of experience delivering advanced imaging technologies to healthcare providers nationwide.

GlobeNewsWire • Feb 19, 2026

Nanox to Showcase Nanox.ARC Live in Europe for First Time and Present New AI Capabilities at ECR 2026

PETACH TIKVA, Israel, Feb. 17, 2026 - NANO-X IMAGING LTD (“Nanox” or the “Company”, Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it will showcase its Nanox.ARC digital tomosynthesis system live in Europe for the first time and present new AI solutions in development at the European Congress of Radiology (ECR), taking place March 4-8, 2026 in Vienna, Austria.

GlobeNewsWire • Feb 17, 2026

Nanox Receives FDA 510(k) Clearance for TAP2D New Image Enhancement Capability for Nanox.ARC and Nanox.ARC X Systems

This clearance enables the next phase of development aimed ultimately at removing the adjunct use in the US

GlobeNewsWire • Feb 3, 2026

Nanox Expands in Europe with New Nanox.ARC Distribution Engagement in Serbia, Montenegro, and Bosnia and Herzegovina

Collaboration with Adriamed drives commercial expansion and strengthens Nanox's regional leadership Engagement supports continued growth across multiple European markets, following recent collaborations in Greece, Romania, Czech Republic and France PETACH TIKVA, ISRAEL – January 14, 2026 – Nanox Imaging Ltd. (“Nanox”, Nasdaq: NNOX), a leader in innovative medical imaging technology, today announced a new collaboration with Adriamed d.o.o.

GlobeNewsWire • Jan 14, 2026

Nano-X Imaging Remains Underwhelming Despite Recent Wins

Nano-X Imaging remains a 'sell' due to weak revenue growth, worsening losses, and limited traction in its core business. NNOX's advanced imaging technology and AI offerings have yet to translate into significant sales, with most revenue still from teleradiology services. Recent partnerships and acquisitions, including VasoHealthcare IT and European distribution deals, offer potential but lack a clear financial impact.

Seeking Alpha • Nov 27, 2025

Why Nano X Imaging Stock Crushed it Today

It signed a distribution deal with a French partner. This followed similar arrangements made in other European countries.

The Motley Fool • Nov 25, 2025

Nanox Engages with Althea France to Accelerate European Commercialization of Nanox.ARC System

Althea France, part of  one of Europe's largest independent medical technology services provider s , to distribute CE-marked Nanox.ARC system across French healthcare sector

GlobeNewsWire • Nov 25, 2025

Nanox.AI Bone Solutions, Advanced AI-Powered Software for Spine Assessment, Recommended by NICE for Early Value Assessment in UK National Health Service hospitals

Nanox's HealthOST and HeathVCF recommended for use in UK National Health Service hospitals for a three-year period as the use of AI solutions in bone disease is evaluated

GlobeNewsWire • Nov 24, 2025

Nanox Announces $15 Million Registered Direct Offering of Common Stock

PETACH TIKVA, Israel, Nov. 23, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company”, Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it has entered into a securities purchase agreement with a single institutional investor for the purchase and sale of 3,826,530 ordinary shares (“Common Stock”) in a registered direct offering. The offering is expected to result in gross proceeds of approximately $15 million, before deducting offering expenses.

GlobeNewsWire • Nov 24, 2025

Why Nano-X Imaging Stock Skyrocketed by 26% on Friday

The visualization specialist posted its third quarter results. It beat on the bottom line and missed slightly on revenue, but investors were cheered by other developments.

The Motley Fool • Nov 21, 2025